Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian early arthritis cohort

Journal of Rheumatology

Volumn 40, Issue 11, 2013, Pages 1823-1830

  Harris, Jamie A ^a   Bykerk, Vivian P ^b   Hitchon, Carol A ^c   Keystone, E C ^d   Thorne, J Carter ^e   Boire, Gilles ^f   Haraoui, Boulos ^g   Hazlewood, Glen ^d   Bonner, Ashley J ^h   Pope, Janet E ^a,i  

^a WESTERN UNIVERSITY   (Canada)

^b Hospital for Special Surgery Inflammatory Arthritis Center   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^f UNIVERSITÉ DE SHERBROOKE   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

DISEASE PROGRESSION; OUTCOME ASSESSMENT; PROFESSIONAL PRACTICE; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME

Indexed keywords

BIOLOGICAL PRODUCT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; RHEUMATOID FACTOR; STEROID;

ADULT; ARTICLE; CANADIAN; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE DURATION; DRUG USE; ETHNIC GROUP; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; STEROID THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

DISEASE PROGRESSION; OUTCOME ASSESSMENT; PROFESSIONAL PRACTICE; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84887427604     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121316     Document Type: Article

References (32)

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
2. Cohen JD, Dougados M, Goupille P, Cantagrel A, Meyer O, Sibilia J, et al. Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. J Rheumatol 2006;33:1936-41.
3. Haraoui B, Pope J. Treatment of early rheumatoid arthritis: concepts in management. Semin Arthritis Rheum 2011;40:371-88.
4. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6.
5. da Silva JA, Phillips S, Buttgereit F. Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scand J Rheumatol Suppl 2011;125:6-11.
6. Fleischmann RM, Stern RL, Iqbal I. Treatment of early rheumatoid arthritis. Mod Rheumatol 2005;15:153-62.
7. Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpä ä S, Hannonen P, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy Trial. Arthritis Res Ther 2010;12:R122.
8. Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011; 70:611-5.
9. Resman-Targoff B, Cicero MP. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care Suppl 2010;16:S249-58.
10. Ma MH, Scott IC, Kingsley GH, Scott DL. Remission in early rheumatoid arthritis. J Rheumatol 2010;37:1444-53.
11. Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Étude et Suivi des Polyarthrites IndifféRenciées récentes (Study and Followup of Early Undifferentiated Polyarthritis). Arthritis Rheum 2011;63:1804-11.
12. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
13. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
14. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
15. Network of Early Arthritis Researchers (NEAR). Canadian Early Arthritis Cohort (CATCH): a prospective cohort study of adults with new-onset inflammatory arthritis symptoms studied by the Network of Early Arthritis Researchers (NEAR). NEAR Protocol for Ethics Submission; 2007.
16. Goodson NJ, Farragher TM, Symmons DP. Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. J Rheumatol 2008;35:945-9.
17. Linde L, Sørensen J, Østergaard M, Hørlev-Petersen K, Rasmussen C, Vendelbo D, et al. What factors influence the health status of patients with rheumatoid arthritis measured by the SF-12v2 health survey and the health assessment questionnaire? J Rheumatol 2009;36:2183-9.
18. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2007;46:342-9.
19. Mattey DL, Dawes PT, Fisher J, Brownfield A, Thomson W, Hajeer AH, et al. Nodular disease in rheumatoid arthritis: association with cigarette smoking and HLA-DRB1/TNF gene interaction. J Rheumatol 2002;29:2313-8.
20. Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009;36:1180-7.
21. McCollum L, Pincus T. A biopsychosocial model to complement a biomedical model: patient questionnaire data and socioeconomic status usually are more significant than laboratory tests and imaging studies in prognosis of rheumatoid arthritis. Rheum Dis Clin North Am 2009;35:699-712.
22. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:137-46.
23. Rupp I, Boshuizen HC, Roorda LD, Dinant HJ, Jacobi CE, van den Bos G. Poor and good health outcomes in rheumatoid arthritis: the role of comorbidity. J Rheumatol 2006;33:1488-95.
24. Skapenko A, Prots I, Schulze-Koops H. Prognostic factors in rheumatoid arthritis in the era of biologic agents. Nat Rev Rheumatol 2009;5:491-6.
25. Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev- Petersen K, Luukkainen RK, et al. Remission in rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008;58:2642-51.
26. Van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009;60:2262-71.
27. Bykerk VP, Pooneh A, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559-82.
28. Pease C, Pope JE, Thorne C, Haraoui BP, Truong D, Bombardier C, et al. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the Optimization of Adalimumab trial. J Rheumatol 2010;37:2469-74.
29. Zummer M. Unequal access to therapies: Canada giveth and the provinces taketh away. CRAJ 2006;16:6-7.
30. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1 year results of a randomized trial. Lancet 2009;374:459-66.
31. Moreland LW, O'Dell JR, Paulus H, Curtis JR, Bridges SL, Zhang X, et al. TEAR: Treatment of early aggressive rheumatoid arthritis: a randomized, double-blind 2 year trial comparing immediate triple DMARD vs. methotrexate and etanercept to step-up from initial methotrexate monotherapy [abstract]. Arthritis Rheum 2009;60 Suppl 10:1895.
32. Peterfy C, Haraoui B, Durez P, Patra K, Kupper H. Decreased incidence of synovitis, osteitis, and erosion in early RA patients treated with adalimumab plus methotrexate compared to those with methotrexate alone: high field MRI analysis from OPTIMA [abstract]. Arthritis Rheum 2010;62 Suppl 10:123.